What Has Been the Growth of the Kcentra Market So Far?
The kcentra market has seen considerable growth due to a variety of factors.
• In recent times, the kcentra market size has experienced XX (HCAGR). The growth trajectory projects an increase from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%.
Factors contributing to this growth during the previous period include an increase in bleeding disorders, heightened awareness of bleeding complications, regulatory approvals for PCC products, a rise in trauma cases and surgeries, and an increased application of anticoagulant therapies.
What Are the Future Growth Projections for the Kcentra Market?
The kcentra market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are set for the kcentra market size to experience an XX% (FCAGR) growth in the upcoming years. The projected growth will push its value to an impressive $XX million in 2029, yielding a compound annual growth rate (CAGR) of XX%.
The significant expansion forecasted for the impending years is attributed to factors such as the increasing elderly population, an uptick in the demand for anticoagulant reversal agents, the broadening access to healthcare in budding economies, a heightened emphasis on patient safety during surgical procedures, and a widening of product indications by respective regulatory authorities. The forecast period is also set to witness major trends such as a surge in personalized medicine, the adoption of point-of-care testing, advancements in plasma-derived products, the incorporation of AI in coagulation management, and a growing preference for single-dose therapies.
What Are The Core Factors Supporting Growth In The Kcentra Market?
The kcentra market is projected to grow, fueled by an increasing incidence of bleeding disorders. Conditions such as hemophilia, von Willebrand disease (VWD), and acquired coagulopathies, which hinder the blood's clotting capacity, can result in extended or excessive bleeding. The growing incidence of bleeding disorders can be attributed to genetic influences, advancements in diagnostic procedures, and increased awareness, allowing for more accurate case identification worldwide. Kcentra, which is a prothrombin complex concentrate, serves as a treatment option for bleeding disorders, particularly in individuals experiencing bleeding associated with vitamin K antagonists or warfarin. In October 2023, for example, the World Federation of Hemophilia, a Canadian non-profit organization, presented estimates showing the prevalence of hemophilia to be approximately 17.1 and 3.8 per 100,000 males for hemophilia A and B respectively. Severe cases were found to be much less frequent, at 6.0 and 1.1 per 100,000 respectively. This equates to nearly 830,895 patients worldwide, including 282,266 with acute forms, and over 257,146 identified hemophilia cases, including 208,957 of hemophilia A and 42,203 of hemophilia B, in addition to over 100,000 cases of von Willebrand disease. Consequently, the increasing incidence of bleeding disorders is propelling the kcentra market forward.
What Are The Major Segments Within The Global Kcentra Market?
The kcentra market covered in this report is segmented –
1) By Indication: Urgent Reversal Of Warfarin Therapy, Treatment Of Acquired Coagulation Factor Deficiency, Management Of Major Bleeding Events
2) By Formulation: Injectable Formulation, Lyophilized Powder For Reconstitution
3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Outpatient Surgical Centers, Emergency Departments, Specialty Clinics
Pre-Book The Kcentra Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Kcentra Market?
The kcentra market is seeing significant changes with the introduction of new therapeutic treatments like balfaxar (human prothrombin complex concentrate), pushing the industry's competitive boundaries forward. Balfaxar, created for the immediate reversal of coagulation factor deficiency caused by warfarin therapy in adults needing emergency surgery or invasive procedures, paves the way for industry advancement. Specifically, Octapharma USA, an American pharmaceutical company, disclosed in July 2023 that the U.S. Food and Drug Administration (FDA) sanctioned the use of Balfaxar (prothrombin complex concentrate, human-lens, also referred to as octaplex in Europe and Canada) as an emergency solution for coagulation factor deficiency due to vitamin K antagonist (VKA, such as warfarin) therapy for adult patients in need of urgent surgery or invasive actions. Balfaxar works by replenishing the clotting factors lacking due to warfarin therapy, thus restoring blood coagulation.
Who Are the Key Players In The Kcentra Market?
Major companies operating in the kcentra market include:
• CSL Behring
What Is The Most Dominant Region In The Kcentra Market?
North America was the largest region in the kcentra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kcentra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
